Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00577902 · ClinicalTrials.gov registry record

Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation

A clinical trial of Head and Neck Cancer, sponsored by University of Arkansas.

Completed
Registry status
37
Enrollment target
1
Study location

NCT00577902: Completed study of Head and Neck Cancer, sponsored by University of Arkansas.

NCT00577902 is a study of Head and Neck Cancer that has completed, run by University of Arkansas. The registered enrollment target is 37 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00577902, a study of Head and Neck Cancer, has completed, sponsored by University of Arkansas.

COMPLETED
Registry status
37 participants
Enrollment target
1
Study location

Study Summary

This study is being conducted to define the specific nutritional biomarkers and nutritional risk during the course of chemoradiation therapy for cancers of the head and neck. This prospective, longitudinal observational study is focused on specific antioxidants and B vitamins. The ORAC was selected as an index of overall antioxidant capacity. We chose to evaluate antioxidant status because administering antioxidants has been shown to reduce chemotherapeutic agent toxicities.

Conditions Studied

Interventions

  • OTHER Observation

Study Locations (1)

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2005-06
Est. Completion 2010-11
University of Arkansas

318 total trials

What the finished NCT00577902 record still lists

NCT00577902 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.

NCT00577902 reports a single indexed study location in Arkansas.

Frequently Asked Questions

What is clinical trial NCT00577902 about?

NCT00577902 is a clinical study titled "Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation". This study is being conducted to define the specific nutritional biomarkers and nutritional risk during the course of chemoradiation therapy for cancers of the head and neck. This prospective, longitudinal observational study is focused on specific antioxidants and B vitamins. The ORAC was selected ...

What is the current status of trial NCT00577902?

This trial is currently completed. The enrollment target is 37 participants. The study started on 2005-06. Estimated completion is 2010-11.

What conditions does trial NCT00577902 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT00577902?

The interventions under investigation include: Observation (OTHER).

Who is sponsoring clinical trial NCT00577902?

This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00577902 being conducted?

This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00577902's enrollment target sits among peer trials

37 159th of 250 higher than 89 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00577902, the US trial registry maintained by the National Library of Medicine. NCT00577902 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.